

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO - 1449 FORM <div style="text-align: right; margin-top: -20px;">  </div>	ATTY. DOCKET NO. 11245/48601	SERIAL NO. 09/635,974
	APPLICANT Thomas Teufel	
	FILING DATE August 9, 2000	GROUP 1643

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCL ASS	FILING DATE
---------------------	------------------	----------------	------	-------	--------------	----------------

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
						NO

OTHER DOCUMENTS

AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
PKT		Cunningham, D., et al., ABSTRACT "Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan- Refractory Metastatic Colorectal Cancer", The New England Journal of Medicine 351:337-45., July 22, 2004
PKT		Lenz, H., et al., ABSTRACT "Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines", Journal of Clinical Oncology, Vol.24, No.30, page 4914-4921 October 20, 2006
PKT		Trivin, F, et al., Letter to the Editor "Complete Sustained Regression of Extensive Psoriasis with Cetuximab Combination Chemotherapy", Acta Oncologica Vol.43, No.6, page 592-593, 2004

EXAMINER /Parithosh K Tungaturthi/	DATE CONSIDERED 01/26/2007
--	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.